Skip to main content
Health technology assessment

Health technology assessment

Search complete. 115 mentions across 20 episodes found for "Health technology assessment".

Sep 19, 2026

Unknown podcast

Supportive Care RWE, Cell Therapy Budget Impact, Patient-Centric HTA

Sep 19 · 18 Mentions

MarcusHOST
0:00
Welcome to the Access Brief, your daily briefing on what's moving in HEOR, HTA, and market access.
MarcusHOST
0:06
I'm Marcus, and it's great to have you with us today.
SarahHOST
0:08
And I'm Sarah.
MarcusHOST
0:30
Then the budget impact challenges for cell and gene therapies.
MarcusHOST
0:36
A, a critical bottleneck for innovative therapies.
MarcusHOST
0:39
And finally, the impact of patient centricity on HTA methodologies in Europe.
MarcusHOST
0:44
B, a shift reshaping value assessments.
SarahHOST
0:49
That second one is particularly interesting to me.
Danielle FisherHOST
0:44
Pascal is the director of the Sydney Melanoma Diagnostic Centre at Royal Prince Alfred Hospital, a professorial research fellow at the University of Sydney, and a faculty member of Melanoma Institute Australia.
Danielle FisherHOST
0:55
We're joined in the studio today by Professor Rachel Morton, Director of Health Economics and Health Technology Assessment at Sydney Clinical Trial Centre, the University of Sydney, and a Melanoma Institute Australia faculty member.
Danielle FisherHOST
1:07
We're also delighted to have Professor Victoria Marr and Dr Amelia Smith joining us virtually.
Danielle FisherHOST
1:13
Tori is the Director of the Victorian Melanoma Service at the Alfred and Professor of Dermato-Oncology at the School of Public Health and Preventative Medicine, Monash University.

Unknown podcast

HCA Warning, Leqembi, FTC, ICER Expansion

Sep 18 · 10 Mentions

MarcusHOST
0:00
Welcome to the Access Brief, your daily briefing on what's moving in HEOR, HTA, and Market Access.
MarcusHOST
0:05
I'm Marcus, and it's great to have you with us today.
SarahHOST
0:08
And I'm Sarah.

6 MINS LATER

SarahHOST
5:54
Otherwise, we risk a system where the middlemen are determining access based on opaque criteria.
MarcusHOST
6:00
ICER announced an expansion of its early phase scientific advice program to cover phase two and early phase three trials.
MarcusHOST
6:06
This aims to help companies design trials that generate evidence acceptable to HTA bodies.
MarcusHOST
6:12
The expansion reflects a growing recognition that early evidence new strategy is critical for market access.
SarahHOST
6:18
This is a smart move by ICER.
Michelle MartinHOST
1:16
Speak with her about her perspective on embedding patient's voice across the healthcare system, not just here in Singapore, across the world as well.
Michelle MartinHOST
1:23
What does it really mean to put the patient's voice at the heart of healthcare? Let's meet Anne Singel, CEO of the Patient Voice Initiative and also President of Health Technology Assessment International.
Michelle MartinHOST
1:35
Good morning, Anne.
Michelle MartinHOST
1:36
Thank you so much for joining us.
Michelle MartinHOST
1:47
So
Ann SingleGUEST
1:47
here in Australia, one of the things I do is we focus in Patient Voice Initiative on bringing patient knowledge to the decision makers who make decisions about what is needed on our healthcare system here.
Ann SingleGUEST
2:03
So that process behind it is called Health Technology Assessment.
Ann SingleGUEST
2:08
And really, it's trying to determine whether something is good value for the health system.
Beth PotterGUEST
1:04
I think what our program really offers is at the MSc level, we offer training that gives everyone a solid basis in epidemiology and applied health research from a breadth perspective, but then they also have an opportunity to focus their work in a specific area of interest.
Beth PotterGUEST
1:22
So our MSc program has six concentrations in clinical research, epidemiology, global health research, health policy, health technology assessment, and implementation science.
Beth PotterGUEST
1:36
And so students have, there are some common courses that everyone takes, but then they also take a package of methodological and content-oriented courses in their specific area of interest.
speaker_1HOST
1:48
The PhD program is very tailored
Beth PotterGUEST
2:55
So with universities or hospital research institutes, public health settings, governmental and non-governmental organizations.
Beth PotterGUEST
3:02
And students work in roles such as research coordinator or research associate.
Beth PotterGUEST
3:08
Program Manager, Data Analyst, Program Evaluator, Knowledge Broker in Health Technology Assessment and Health Economics.
speaker_1HOST
3:17
How does the program support student development and mentorship?

Unknown podcast

Access Erosion Signals & Value Frameworks

Sep 15 · 4 Mentions

MarcusHOST
0:00
Welcome to the Access Brief, your daily briefing on what's moving in HEOR, HTA, and market access.
MarcusHOST
0:06
I'm Marcus, and it's great to have you with us today.
SarahHOST
0:08
And I'm Sarah.
SarahHOST
1:17
We're seeing more references to system sustainability in coverage decisions, which translates to higher evidence bars for novel therapies.
MarcusHOST
1:28
What strikes me about that is the timing.
MarcusHOST
1:30
With IRA implementation accelerating, this could be the first real-world test of whether price negotiation authority correlates with tougher HTA requirements.
MarcusHOST
1:38
If HCA's struggles lead to more coverage denials, it creates a vicious cycle.
SarahHOST
1:43
The part that gives me pause is whether this is temporary or structural.

Unknown podcast

Global HTA Shifts & Digital Health

Sep 12 · 8 Mentions

MarcusHOST
0:00
Welcome to the Access Brief, your daily briefing on what's moving in HEOR, HTA, and market access.
MarcusHOST
0:05
I'm Marcus, and it's great to have you with us today.
SarahHOST
0:08
And I'm Sarah.
MarcusHOST
0:34
Canada's CAD combination products pilot.
MarcusHOST
0:37
Exploring value assessment for complex therapies.
MarcusHOST
0:40
And NICE's expanding global influence on HTA standards.
MarcusHOST
0:44
It gets to Wasa Sherpin Prasinder, reshaping international benchmarking.
SarahHOST
0:48
That first one hits home for me.

Unknown podcast

HCA Warning & Leqembi Shift

Sep 11 · 7 Mentions

MarcusHOST
0:00
Welcome to the Access Brief, your daily briefing on what's moving in HEOR, HTA, and Market Access.
MarcusHOST
0:06
I'm Marcus, and it's great to have you with us today.
SarahHOST
0:08
And I'm Sarah.
SarahHOST
4:17
The subcutaneous route expands the treatable population to those who couldn't tolerate IV infusions.
SarahHOST
4:25
That's a population level access shift, not just a convenience factor.
SarahHOST
4:29
The HTA bodies will need to adjust their decision trees accordingly.
MarcusHOST
4:34
Exactly.
MarcusHOST
4:35
Now, the FTC settlement with CVS Caremark, this is a landmark moment.
Paul CrossHOST
10:21
And that's going to terrify some people, but there's no point being terrified by it.
Paul CrossHOST
10:25
So when I think of health technology assessment, my concern expressed this week was that, well, people are using it for submissions.
Paul CrossHOST
10:30
Evaluators are using it to evaluate those submissions.
Paul CrossHOST
10:33
And I bet discussants are using it to build their presentations.

Unknown podcast

CMS Gene Therapy Coverage & RWE Integration

Sep 10 · 10 Mentions

MarcusHOST
0:00
Welcome to the Access Brief, your daily briefing on what's moving in Huer, HTA, and market access.
MarcusHOST
0:05
I'm Marcus, and it's great to have you with us today.
SarahHOST
0:08
And I'm Sarah.
SarahHOST
0:15
The gene therapy coverage shifts alone are keeping me busy.
MarcusHOST
0:19
Same here.
MarcusHOST
0:20
We're looking at CMS Part D gene therapy coverage updates, significant implications for reimbursement pathways, then FDA draft guidance on RWE for post-marketing studies, potentially reshaping evidence generation, and nice digital therapeutics HTA framework update.
MarcusHOST
0:38
Current, a critical evolution for novel modalities.
MarcusHOST
0:42
Finally, EU Critical Medicines Act.

10 more episodes mention Health technology assessment.

Create an account to see the whole feed, search across every transcript, and follow the entities you care about.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.